A heart-monitoring platform can track up to 11 body signals. iRhythm bought VitalConnect.
iRhythm Holdings has completed its acquisition of VitalConnect, expanding its cardiac monitoring platform with mobile cardiac telemetry and multi-vitals monitoring capabilities. The acquisition involved $237.5 million in cash and up to 423,334 shares, with an additional $10 million in working capital provided to VitalConnect. iRhythm expects this strategic move to enhance its revenue growth starting in 2027 while maintaining its 15% adjusted EBITDA margin target for the same year.
IRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
iRhythm Holdings, Inc. (Nasdaq: IRTC) has announced the completion of its acquisition of Vital Connect, Inc., a leader in wearable biosensor technology and ambulatory cardiac monitoring. This acquisition broadens iRhythm's cardiac monitoring portfolio, advances its multi-vitals strategy, and expands its addressable market across the continuum of care, including inpatient and hospital-to-home settings. The transaction is expected to enhance iRhythm's revenue growth rate starting in 2027 while maintaining its 15% adjusted EBITDA margin target for the same year.
iRhythm Holdings Finalizes Acquisition of Vital Connect Through iRhythm Technologies
iRhythm Holdings, Inc. announced the successful completion of its acquisition of Vital Connect, Inc. through its wholly owned subsidiary, iRhythm Technologies, Inc. The acquisition was finalized on October 5, 2026, making Vital Connect an indirect wholly owned subsidiary of iRhythm Holdings. Financial details of the transaction were not disclosed in the Form 8-K filing.
Patient insurance numbers and birth dates were in data downloaded during iRhythm's cyber incident
iRhythm Holdings (IRTC) has begun notifying individuals affected by a cybersecurity incident that occurred between June 3 and June 8, 2026. Unauthorized individuals accessed and downloaded patient data including names, contact details, account and insurance numbers, device serial numbers, service dates, and birth dates. The company states there is no evidence of financial account or payment card information being compromised and believes the incident is not likely to have a material financial impact.
Wells Fargo Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Maintains Target Price $168
Wells Fargo has reiterated its Buy rating for iRhythm Technologies (IRTC.US) and maintained its target price at $168. This indicates the firm's continued confidence in the company's financial prospects and stock performance.
iRhythm Technologies stock reports 20.1 percent revenue growth
iRhythm Technologies reported Q2 2026 revenue of $224.17 million, marking a 20.1% increase year-over-year and beating analyst estimates. The company achieved adjusted EPS of $0.58, significantly exceeding expectations. Additionally, the Hart-Scott-Rodino waiting period for the Vital Connect acquisition expired, with the deal expected to close in early October 2026.
iRhythm Holdings, Inc. (IRTC) stock price, news, quote and history
This article provides a comprehensive overview of iRhythm Holdings, Inc. (IRTC) stock, including its current price, historical data, key statistics, and company profile. It details iRhythm's digital healthcare business, focusing on ambulatory cardiac monitoring services and devices like the Zio system, and offers recent performance metrics, earnings trends, and analyst insights. The stock experienced a slight pre-market decline after closing at $111.75, with a 1-year return of 36.31% and a market cap of $3.684 billion.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into iRhythm Technologies, Inc. (NASDAQ:IRTC) regarding potential corporate wrongdoing. The firm encourages shareholders who purchased iRhythm securities before January 11, 2022, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis for class actions.
Trading Systems Reacting to (IRTC) Volatility
Irhythm Technologies Inc. (NASDAQ: IRTC) is showing weak near-term sentiment, potentially signaling a resumption of long-term weakness. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss zones. A mid-channel oscillation pattern is identified, with an exceptional 65.0:1 risk-reward setup targeting an 18.9% gain versus 0.3% risk.
iRhythm at Wells Fargo 21st annual healthcare conference: vitalconnect deal expands reach
iRhythm Technologies Inc. presented its growth strategy at the Wells Fargo 21st Annual Healthcare Conference, focusing on the VitalConnect acquisition, new product launches, and commercial expansion. The company aims to broaden its access to the mobile cardiac telemetry market, despite anticipating slower revenue growth in the second half of 2026 due to tougher comparisons and pricing benefits not repeating. Management expressed confidence in achieving 30-40% market share in the mobile cardiac telemetry segment over time and reiterated its goal of exceeding $1 billion in revenue by 2027.
iRhythm To Buy VitalConnect, Plugging 30-Day MCT Gap And Broadening Its Cardiac Monitoring Platform
iRhythm Technologies is set to acquire VitalConnect, a move that will expand iRhythm's cardiac monitoring platform. This acquisition is significant as it will allow iRhythm to cover the 30-day mobile cardiac telemetry (MCT) gap, enhancing its existing range of cardiac monitoring solutions. The integration of VitalConnect's technology is expected to broaden iRhythm's capabilities in the cardiac monitoring market.
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) concerning corporate wrongdoing. The firm encourages investors who purchased iRhythm securities before January 11, 2022, and still hold them, to assist in the investigation. The firm operates on a contingency fee basis, only seeking reimbursement if successful in recovering funds for investors.
IRMD stock trades steadily as iRhythm Technologies posts strong Q2 2026 growth
iRhythm Technologies (IRMD) stock is trading steadily around $123.07 in early September 2026, driven by strong Q2 2026 financial results. The company reported a significant revenue increase of 37.3% year-over-year to $563.0 million and improved adjusted gross margins, indicating robust growth in its digital cardiac monitoring business. Analyst sentiment remains positive, reflecting expectations for continued growth and profitability in the health technology sector.
iRhythm Technologies Inc. (IRTC) Key Financial Ratios – Valuation, Profitability & More
This article provides a detailed analysis of iRhythm Technologies Inc. (IRTC) key financial ratios, covering valuation, profitability, growth, solvency, and operating efficiency. It presents comparative data against peer medians for various metrics like Return on Equity, Net Margin, Revenue Growth, and Debt to Equity. The report highlights IRTC's performance in different financial areas up to TTM (Trailing Twelve Months) and annual periods.
Mobile ECG Devices Market Outlook 2025-2035 Featuring Profiles AliveCor, Apple and iRhythm Technologies - Industry Forecast to Reach $9.03 Billion by 2035 as Remote Cardiac Monitoring Adoption Accelerates
The global mobile ECG devices market is projected to reach $9.03 billion by 2035, driven by increased adoption of remote cardiac monitoring and digital health solutions. The market, which was valued at $3.16 billion in 2025, is experiencing strong growth due to factors like the rising prevalence of cardiovascular diseases, an aging population, and the expansion of telemedicine. Key trends include AI-enabled wearables and point-of-care ECG solutions, with North America leading regional revenue and Asia-Pacific showing the fastest growth.
Mobile ECG Devices Market Outlook 2025-2035 Featuring
The global mobile ECG devices market is projected to reach $9.03 billion by 2035, driven by the increasing adoption of remote cardiac monitoring, wearable technologies, and digital health solutions. Opportunities are emerging from AI-enabled wearable ECG bands, remote monitoring, point-of-care diagnostics, and home use, supported by telemedicine and preventive care, especially in emerging markets. North America was the largest regional market in 2025, while Asia-Pacific and the Middle East are expected to show the fastest growth.
Understanding Momentum Shifts in (IRTC)
This article analyzes Irhythm Technologies Inc. (NASDAQ: IRTC), identifying weak sentiment across all horizons and suggesting a short bias. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes an exceptional 55.3:1 risk-reward short setup targeting a 15.8% downside.
IRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference
IRhythm Holdings (NASDAQ:IRTC), a leading digital healthcare company, announced its participation in the upcoming Wells Fargo 21st Annual Healthcare Conference. The company's President and CEO, Quentin Blackford, and CFO, Daniel Wilson, are scheduled to present on September 7, 2023, at 1:40 PM ET. A live webcast of the presentation will be accessible on the company's investor relations website.
Bronstein, Gewirtz & Grossman, LLC Encourages iRhythm Technologies, Inc. (IRTC) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against iRhythm Technologies, Inc. (IRTC) for corporate wrongdoing. The firm encourages investors who purchased iRhythm securities before January 11, 2022, and still hold them, to contact them to assist in the securities investigation. The firm operates on a contingency fee basis, meaning investors incur no upfront cost.
Freedom Capital cuts iRhythm Technologies stock price target on valuation By Investing.com
Freedom Capital has lowered its price target for iRhythm Technologies (NASDAQ: IRTC) to $190 from $200, while maintaining a Buy rating, citing the stock's overvaluation despite strong Q2 results. The company reported impressive revenue growth and increased its fiscal 2026 EBITDA guidance, also expanding its portfolio with the acquisition of VitalConnect. Analysts still anticipate profitability for iRhythm this year, with further product approvals expected in early 2027.
Freedom Capital cuts iRhythm Technologies stock price target on valuation By Investing.com
Freedom Capital has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) shares from $200 to $190, while maintaining a Buy rating. This adjustment comes despite iRhythm exceeding second-quarter revenue and EBITDA expectations, with strong growth and improved profitability. The firm cited valuation as the reason for the target cut, noting the stock appears overvalued relative to its Fair Value estimate.
William Blair Maintains IRhythm Technologies(IRTC.US) With Buy Rating
William Blair analyst Brandon Vazquez has maintained a "Buy" rating on iRhythm Technologies (IRTC.US). Vazquez has a 41.8% success rate and a -2.5% average return over the past year, according to TipRanks data. The article includes disclaimers that the information is for educational purposes only and not investment advice.
Citizens Financial Group Inc. RI Buys New Shares in iRhythm Technologies $IRTC
Citizens Financial Group Inc. RI has acquired a new stake of 48,960 shares in iRhythm Technologies, valued at approximately $9.29 million, representing about 0.15% of the company. Despite recent target-price reductions, analysts maintain a "Moderate Buy" consensus with an average price target of $179.93 for IRTC. iRhythm Technologies also reported strong quarterly results, with revenue up 20.1% year over year and earnings per share beating analyst expectations.
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of iRhythm stock to contact them to discuss their legal rights and options, including seeking corporate governance reforms or the return of funds to the company. Halper Sadeh LLC emphasizes that shareholder involvement can enhance transparency, accountability, and overall shareholder value.
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)
Analysts from Bank of America Securities and Jefferies have issued bullish sentiments on several healthcare companies. 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO), and Irhythm Technologies (IRTC) all received Buy ratings, with analysts citing significant upside potential from current levels. The article highlights specific analyst ratings, price targets, and the consensus among analysts for each company.
Citi Sticks to Their Buy Rating for Irhythm Technologies (IRTC)
Citi has reiterated a Buy rating for Irhythm Technologies (IRTC) with a price target of $157.00. This comes despite a GAAP net loss for the company in its latest quarter, though revenue increased. Analyst consensus on the stock remains a Strong Buy, but insider sentiment is negative due to recent share sales.
iRhythm Technologies $IRTC Shares Sold by Bank of America Corp DE
Bank of America Corp DE reduced its stake in iRhythm Technologies by 41.7% in Q1, selling over 309,000 shares but still holding shares worth $51 million. Despite this reduction, iRhythm reported strong Q1 results with revenue up 20.1% year-over-year and earnings exceeding analyst expectations. The company maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $179.93.
iRhythm Technologies (NASDAQ:IRTC) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have given iRhythm Technologies (NASDAQ:IRTC) an average recommendation of "Moderate Buy," with a consensus price target of $179.93. The company recently reported strong quarterly earnings, beating expectations with an EPS of $0.58 and revenue of $224.17 million, a 20.1% year-over-year increase. Institutional investors, including Royal Bank of Canada and Goldman Sachs, have also increased their holdings in IRTC.
iRhythm Technologies $IRTC Shares Acquired by Quantinno Capital Management LP
Quantinno Capital Management LP significantly increased its stake in iRhythm Technologies (NASDAQ:IRTC) by 1,172.8% in the first quarter, now owning 18,621 shares valued at approximately $2.2 million. The company reported strong financial results, with quarterly revenue up 20.1% year over year to $224.17 million and EPS of $0.58, greatly surpassing analyst estimates. Despite some target price adjustments by analysts, iRhythm Technologies maintains a "Moderate Buy" consensus rating with an average price target of $179.93.
The Technical Signals Behind (IRTC) That Institutions Follow
This article provides a technical analysis of Irhythm Technologies Inc. (NASDAQ: IRTC), detailing institutional trading strategies based on AI models. It identifies strong near- and mid-term sentiment but a weak long-term outlook, with key support and resistance levels. The analysis also highlights a significant risk-reward short setup for the stock.
iRhythm Technologies (NASDAQ:IRTC) Stock Price Expected to Rise, Truist Financial Analyst Says
Truist Financial has increased its price target for iRhythm Technologies (NASDAQ:IRTC) from $160 to $168, maintaining a "buy" rating and indicating a potential upside of 34.59%. This positive outlook aligns with a "Moderate Buy" consensus rating from MarketBeat analysts, despite some recent target reductions by other firms. The company recently surpassed earnings estimates, reporting $0.58 per share and a 20.1% year-over-year revenue increase to $224.17 million.
IRhythm to Gain From VitalConnect Deal, Rising Margins, Oppenheimer Says
Oppenheimer expects iRhythm Technologies to benefit from its acquisition of VitalConnect, which will add a significant product to its portfolio and is expected to be immediately accretive to margins. The firm reiterates an Outperform rating and a $170 price target for iRhythm, citing potential for margin expansion through better supply chain management and manufacturing. The analysis suggests that while VitalConnect is a smaller player, its technology complements iRhythm's offerings and enhances the company's competitive position.
Why iRhythm (IRTC) Shares Are Trading Lower Today
Shares of iRhythm Technologies (IRTC) fell after an analyst significantly cut their price target on the stock, despite the company reporting strong quarterly earnings and raising its full-year revenue guidance. Truist lowered its price target to $18 from $160, even while maintaining a "Buy" rating, which caused investor concern. The stock initially dropped but recovered some losses, with analysts suggesting such moves can present buying opportunities for high-quality stocks.
IRhythm grows heart monitoring leadership with $288M VitalConnect buy
IRhythm announced its acquisition of VitalConnect for $287.5 million to expand its mobile cardiac telemetry (MCT) capabilities. This acquisition is expected to unlock access to an additional $500 million market opportunity within the $1 billion cardiac monitoring market. While IRhythm remains committed to securing FDA clearance for its Zio MCT device, the immediate focus will be on integrating VitalPatch into its commercial operations by year-end.
IRTC Q2 Deep Dive: Product Portfolio Expansion and Margin Gains Highlight Quarter
iRhythm Technologies (NASDAQ:IRTC) reported strong Q2 CY2026 results, surpassing revenue and profit expectations, driven by demand for its Zio cardiac monitoring platform and operational efficiencies. The company lifted its full-year revenue guidance, with growth attributed to sustained product demand, effective commercial execution, and strategic margin improvements through automation. Future growth is anticipated from the pending VitalConnect acquisition, expanding into new care settings, and continued investment in technology and direct-to-patient initiatives.
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating iRhythm Technologies, Inc. (IRTC) for potential breaches of fiduciary duties by its officers and directors. The investigation stems from allegations that the company misrepresented the Zio AT monitor's capabilities and market penetration, leading to artificially inflated stock prices. The law firm is encouraging long-term IRTC shareholders to contact them to discuss their rights.
Irhythm Technologies Boosts Outlook, Expands Cardiac Monitoring Platform
iRhythm Technologies (IRTC) recently settled a patent dispute for $50 million and announced strong Q2 2026 results, including a 20.1% revenue increase and improved margins. The company also secured FDA clearance for a new algorithm and plans to acquire Vital Connect for $287.5 million to expand its cardiac monitoring platform. Despite these positive developments, TipRanks' AI analyst, Spark, rates IRTC as "Neutral" due to balance sheet leverage and a bearish technical trend, noting that valuation support is limited by negative earnings and mixed corporate events.
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating iRhythm Technologies, Inc. (NASDAQ: IRTC) for potential breaches of fiduciary duties by its officers and directors. A federal lawsuit alleges that iRhythm insiders misrepresented or failed to disclose that the Zio AT monitor was intended for high-risk patients, leading to artificially inflated stock prices. The firm encourages long-term IRTC shareholders to contact them to enforce their rights, emphasizing that it covers all case costs.
iRhythm Technologies (NASDAQ:IRTC) Rating Lowered to "Hold" at Wall Street Zen
Wall Street Zen has downgraded iRhythm Technologies (NASDAQ:IRTC) to a "Hold" rating from "Buy," despite the company's strong Q2 results and a broader analyst consensus of "Moderate Buy." iRhythm reported earnings of $0.58 per share against an expected loss and saw revenue increase by 20.1% year-over-year. The company also announced the acquisition of VitalConnect for $287.5 million, expanding its cardiac-monitoring portfolio, and provided a positive 2026 revenue outlook.
iRhythm Technologies, Inc. Q2 2026 Earnings Call Summary
iRhythm Technologies reported its seventh consecutive quarter of over 20% revenue growth, driven by strong demand across cardiology, primary care, and international markets. The company announced the acquisition of VitalConnect to expand into new cardiac monitoring modalities and raised its full-year 2026 revenue guidance to $880 million-$890 million. Additionally, iRhythm resolved litigation with Baxter/Welch Allyn for a $50 million settlement and achieved FDA clearance for a new algorithm expected to significantly reduce review time and generate cost savings.
iRhythm advances cardiac monitoring provision with $287.5m VitalConnect acquisition
iRhythm has announced the acquisition of VitalConnect for $287.5 million, a move aimed at expanding its cardiac monitoring platform across various healthcare settings. The deal, expected to close by the end of 2026, combines cash and iRhythm common stock. This acquisition is anticipated to boost iRhythm's Zio platform by integrating VitalConnect's monitoring tools and expanding its market reach, complementing its strong Q2 financial performance with a 20.1% year-over-year revenue increase.
Needham cuts iRhythm Technologies stock price target on lower multiple By Investing.com
Needham has lowered its price target for iRhythm Technologies (NASDAQ: IRTC) to $192.00 from $255.00, while maintaining a Buy rating. This adjustment comes despite iRhythm exceeding second-quarter revenue expectations and raising its 2026 revenue guidance, as well as announcing the acquisition of VitalConnect which is expected to be accretive to growth and expand its market reach. The firm cited a lower target multiple as the reason for the reduced price target, noting that InvestingPro analysis suggests the stock may be overvalued despite its recent performance.
iRhythm Technologies Inc (IRTC) Stock News Today
This article provides current stock information for iRhythm Technologies Inc (IRTC), including its stock price, market capitalization, and a note that more news is coming soon. It also lists various financial and analytical tools available on the TradingKey platform for investors.
Truist Securities Adjusts IRhythm Technologies PT to $168 From $160, Maintains Buy Rating
Truist Securities has increased its price target for iRhythm Technologies (IRTC) to $168 from $160, while reiterating a Buy rating on the stock. This adjustment suggests a positive outlook on the company's future performance by the investment bank.
Needham cuts iRhythm Technologies stock price target on lower multiple
Needham has lowered its price target for iRhythm Technologies (NASDAQ:IRTC) to $192 from $255, while maintaining a Buy rating. The adjustment comes despite iRhythm exceeding Q2 2026 revenue expectations and raising its full-year guidance, partly due to the acquisition of VitalConnect which is expected to boost growth and maintain strong gross margins. Analysts anticipate profitability for iRhythm this year, although the firm's price target was reduced based on a lower target multiple.
IRTC Looks 22.6% Undervalued on GF Value™
iRhythm Technologies, Inc. (IRTC) reported strong Q2 revenue growth of 20.1% year-over-year, leading to raised full-year guidance and a strategic acquisition to expand its cardiac monitoring capabilities. Despite being unprofitable, the company is considered 22.6% undervalued based on its GF Value™ and shows strong fundamentals with a GF Score™ of 79, driven by high growth and valuation ranks. However, mixed guru ownership and net insider selling indicate cautious optimism and suggest that IRTC remains a speculative growth stock.
Earnings call transcript: iRhythm tops revenue view in Q2 2026 and stock rises
iRhythm Technologies (IRTC) reported strong Q2 2026 results, exceeding revenue forecasts and demonstrating significant margin expansion, leading to a stock increase. The company announced the acquisition of VitalConnect, which is expected to expand its cardiac monitoring offerings and accelerate its entry into new markets like inpatient monitoring and hospital-to-home care. iRhythm also raised its full-year 2026 revenue and adjusted EBITDA margin guidance, emphasizing continued focus on profitable growth, innovation, and strategic market expansion.
(IRTC) IRhythm Technologies Expects 2026 Revenue Range $880M - $890M, vs. FactSet Est of $881.1M
iRhythm Technologies (IRTC) has announced its revenue expectations for 2026, forecasting a range of $880 million to $890 million. This projection is in line with FactSet's estimated revenue of $881.1 million for the same period. The company also reported its Q2 2026 earnings, with revenue rising to $224.2 million, surpassing FactSet's estimate of $219.3 million, and adjusted EPS of $0.58, compared to an estimated $0.00.
iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
iRhythm Holdings, Inc. announced its definitive agreement to acquire VitalConnect for approximately $287.5 million, comprising cash and iRhythm common stock. This acquisition is expected to broaden iRhythm's cardiac monitoring platform by adding mobile cardiac telemetry and multi-vitals monitoring capabilities, expanding its addressable market across ambulatory, inpatient, and hospital-to-home care settings. The transaction is projected to enhance iRhythm's revenue growth rate starting in 2027 while maintaining its adjusted EBITDA margin target for the same year.
iRhythm earnings up next: Narrowing losses in focus tonight
iRhythm Technologies Inc. is scheduled to report second-quarter earnings, with analysts expecting a narrower loss of 5 cents per share and revenue of $219.3 million, indicating substantial improvement from the previous quarter. Investors will be focused on the company's ability to maintain rapid growth while accelerating its path to profitability, especially after raising full-year revenue and adjusted EBITDA margin guidance. Despite a significant stock price retreat from its 52-week high, all 15 analysts rate the stock a Buy, with a mean price target suggesting a 42% upside.
